

ACS boosts its commitment against cancer

Madrid, October 19, 2023

As part of the evolution towards new generation projects, the Group has focused on the biopharmaceutical and healthcare sector, being already the "first global player". In the United States, Turner was awarded at the beginning of the year a 680 million pharmaceutical plant that will contribute to the fight against disease, and in Spain, Dragados is already a leader in the development of medical facilities.



Hospital Son Dureta, Palma de Mallorca

October turns pink to commemorate society's commitment against breast cancer. According to figures from the Cancer Observatory of the Spanish Association Against Cancer (AECC), around 34,740 new breast cancers were diagnosed in our country in 2022, which represents almost 30% of cancers diagnosed in women. In this context, and despite the fact that it may go unnoticed, the role played by the ACS Group in tackling the disease is crucial, as the ability to build first-rate specialized medical facilities directly impacts the results of early detection, treatment and research.

Consolidated experience in the fight against cancer in Spain

The company continues to expand its presence and leadership in the area of Biopharmaceuticals and Healthcare, where "the Group is already the world's leading player", as our CEO, Juan Santamaría, said at the company's last meeting with analysts.

The positioning in the healthcare field is understood from the point of view of the permanent evolution of a company that has focused on the so-called "new generation projects" as the fundamental axis around which the present and future development strategy will revolve. These projects are oriented towards sustainability and the digitalization of infrastructures and are grouped into four distinct areas: sustainable mobility, energy transition, digitalization, and healthcare and biopharmaceuticals. These areas represent the essence and commitment of our Group to the values of corporate social responsibility. They are works which already have a significant weight in ACS's activity, but their relevance in a portfolio of activities which quarter after quarter breaks records will continue to increase in the short and medium term.

To illustrate the extent of ACS's specialization in the healthcare sector, specifically in the area of the fight against cancer, it is sufficient to take a look at the portfolio of completed and ongoing projects of our subsidiaries, whose activity is especially concentrated in North America, Asia-Pacific and Europe.

In Spain, this commitment is exemplified by Dragados, one of Spain's leading exponents in the construction of medical facilities. Its experience in oncological care is reflected in a broad portfolio of specialized and multidisciplinary projects throughout Spain.



Hospital La Fe, Valencia

In Valencia, Dragados erected the New La Fe University Hospital, a complex with 35 operating rooms, 6 linear accelerators and 56 radiology rooms, as well as several laboratories and research areas. The project, which was completed in 2017, totals 266,918 m² built. In Barcelona and Toledo, it is present through the Bellvitge Hospital and Toledo University Hospital Complex projects. Between them they have a total of 56 operating rooms and 4 radiotherapy bunkers. Another outstanding facility is located in

the Balearic Islands, more specifically in Palma de Mallorca. The Son Dureta University Hospital, which has 174,054 m² of floor space, has 20 operating rooms, 1 radiotherapy bunker, research and laboratory buildings.

Specialized facilities in the USA

The spearhead in the United States is Turner Construction, which over its more than 120-year history has built a wide variety of facilities that contribute to cancer treatment. Among the most recent projects is the pharmaceutical plant announced in early 2023 in Colorado for about €680 million. The customer will be Agilent Technologies and the facility will serve to develop synthetic oligonucleotides, short DNA sequences that have proven to be of vital importance in treating cardiovascular diseases and tumors.



David H. Koch Center For Cancer Care

This is just the beginning. These are just some of the many projects of our Group, which has become one of the major international benchmarks in the healthcare and biopharmaceutical sector. Focusing on hospitals, Turner's portfolio includes some first-class hospitals exclusively dedicated to the diagnosis, treatment and research of cancer. This is the case of the Olathe Health Cancer Center in Kansas, the D.H. Koch Center for Cancer in Manhattan, which has 23 floors and deals with the latest hematological cancer treatments and radiotherapy, or the Dales & Frances Hughes Cancer Center in Pennsylvania, a top-level center that houses diagnostic and radiotherapy services thanks to its two linear accelerators, used to deliver high-energy X-rays to the tumor region to destroy cancer cells without affecting the surrounding tissues. The latter is also a sustainable facility, as Turner designed the project to LEED Silver standards and included a green roof over the linear accelerator chamber.

It is a reality, the incidence of cancer is on the rise. According to AECC estimates, 1 in 3 women and 1 in 2 men will develop cancer in Spain. And while it is true that survival rates have increased by 20% over the last 20 years and are expected to reach 70% survival in 2030, this disease will be increasingly present in our lives.

The best shield against cancer lies in research. Medical personnel and researchers and physicians are the main defense, but the fight against cancer is a challenge that requires the commitment of all sectors of society. This also applies to construction. And it is precisely this philosophy which positions the ACS Group as the leading global player in Healthcare and Biopharmaceuticals.



Olathe Health Cancer Center